Literature DB >> 24845032

Association of LEP A19G polymorphism with cancer risk: a systematic review and pooled analysis.

Pengcheng Liu1, Hui Shi, Changjia Huang, Hexi Shu, Run Liu, Yunji Yang, Jinpeng Gong, Yong Yang, Ming Cai.   

Abstract

The results from the published studies on the association between leptin (LEP) genetic polymorphism and cancer risk are conflicting. The common A19G (rs2167270) genetic polymorphism has been reported to be functional and may contribute to genetic susceptibility to cancers. However, the association between LEP A19G (rs2167270) genetic polymorphism and cancer risk remains inconclusive. To better understand the role of LEP A19G (rs2167270) genetic polymorphism in global cancer, we conducted this comprehensive meta-analysis encompassing 5,679 cases and 7,443 controls. Overall, the LEP A19G (rs2167270) genetic polymorphism was associated with lower cancer risk. In the stratified analysis, significant associations were found between the LEP A19G (rs2167270) genetic polymorphism and colorectal cancer and non-Hodgkin's lymphoma. For colorectal cancer, there was no significant association of LEP A19G (rs2167270) variant with this disease under heterozygous codominant model [odds ratio (OR) = 1.11 (0.97-1.27)], dominant genetic model [OR = 1.03 (0.91-1.17)], and additive genetic model [OR = 0.94 (0.86-1.03)]; however, there was a marginal association under homozygous codominant model [OR = 0.80 (0.66-0.97)] and recessive genetic model [OR = 0.75 (0.63-0.90)]. For non-Hodgkin's lymphoma, there was a significant association of LEP A19G (rs2167270) variant with the disease under homozygous codominant model [OR = 0.74 (0.59-0.94)], recessive genetic model [OR = 0.76 (0.61-0.94)], and additive genetic model [OR = 0.89 (0.80-0.99)], but not under heterozygous codominant model [OR = 0.95 (0.82-1.10)] and dominant genetic model [OR = 0.91 (0.79-1.04)]. Moreover, a significantly decreased cancer risk was found in recessive genetic model among Latin American population. When stratified by study design, significantly elevated susceptibility to cancer was not found among any studies. No significantly differences in genotype method and sample size in cases were found among genotypes. These findings suggest that the LEP A19G (rs2167270) genetic polymorphism may decrease the susceptibility to cancers in colorectal cancer and non-Hodgkin's lymphoma, when assuming a homozygote codominant model and a recessive genetic model among Latin American population. The phenomenon also indicates that the SNP functions as a recessive mutation, which needs to be verified or linked with functional studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24845032     DOI: 10.1007/s13277-014-2088-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  A functional polymorphism in the promoter region of leptin gene increases susceptibility for non-small cell lung cancer.

Authors:  Ricardo Ribeiro; Ana Paula Araújo; Ana Coelho; Raquel Catarino; Daniela Pinto; António Araújo; Carmen Calçada; Carlos Lopes; Rui Medeiros
Journal:  Eur J Cancer       Date:  2006-04-19       Impact factor: 9.162

2.  Single nucleotide polymorphisms in obesity-related genes and the risk of esophageal cancers.

Authors:  James D Doecke; Zhen Zhen Zhao; Mitchell S Stark; Adèle C Green; Nicholas K Hayward; Grant W Montgomery; Penelope M Webb; David C Whiteman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  Association of LEP and ADIPOQ common variants with colorectal cancer in Mexican patients.

Authors:  Miriam Partida-Pérez; María de la Luz Ayala-Madrigal; Jorge Peregrina-Sandoval; Nelly Macías-Gómez; José Moreno-Ortiz; Evelia Leal-Ugarte; Mario Cárdenas-Meza; Manuel Centeno-Flores; Víctor Maciel-Gutiérrez; Enrique Cabrales; Sergio Cervantes-Ortiz; Melva Gutiérrez-Angulo
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer.

Authors:  Chien-Liang Liu; Yuan-Ching Chang; Shih-Ping Cheng; Schu-Rern Chern; Tsen-Long Yang; Jie-Jen Lee; Ing-Cherng Guo; Chih-Ping Chen
Journal:  Oncology       Date:  2007-11-14       Impact factor: 2.935

7.  Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II.

Authors:  Ming-Hsi Wang; Kathy J Helzlsouer; Michael W Smith; Judith A Hoffman-Bolton; Sandra L Clipp; Viktoriya Grinberg; Angelo M De Marzo; William B Isaacs; Charles G Drake; Yin Yao Shugart; Elizabeth A Platz
Journal:  Prostate       Date:  2009-06-01       Impact factor: 4.104

8.  Antiapoptotic effects of leptin in human neuroblastoma cells.

Authors:  V C Russo; S Metaxas; K Kobayashi; M Harris; G A Werther
Journal:  Endocrinology       Date:  2004-05-27       Impact factor: 4.736

9.  Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma.

Authors:  Kaouther Snoussi; A Donny Strosberg; Noureddine Bouaouina; Slim Ben Ahmed; A Noureddine Helal; Lotfi Chouchane
Journal:  BMC Cancer       Date:  2006-02-20       Impact factor: 4.430

10.  Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms.

Authors:  E V Willett; C F Skibola; P Adamson; D R Skibola; G J Morgan; M T Smith; E Roman
Journal:  Br J Cancer       Date:  2005-10-03       Impact factor: 7.640

View more
  8 in total

Review 1.  Gender Differences in Adipocyte Metabolism and Liver Cancer Progression.

Authors:  Otto K-W Cheung; Alfred S-L Cheng
Journal:  Front Genet       Date:  2016-09-20       Impact factor: 4.599

2.  Investigation of TCF7L2, LEP and LEPR polymorphisms with esophageal squamous cell carcinomas.

Authors:  Hao Qiu; Xunting Lin; Weifeng Tang; Chao Liu; Yu Chen; Hao Ding; Mingqiang Kang; Shuchen Chen
Journal:  Oncotarget       Date:  2017-11-17

Review 3.  Genetic polymorphisms in leptin, adiponectin and their receptors affect risk and aggressiveness of prostate cancer: evidence from a meta-analysis and pooled-review.

Authors:  Meng-Bo Hu; Hua Xu; Ji-Meng Hu; Wen-Hui Zhu; Tian Yang; Hao-Wen Jiang; Qiang Ding
Journal:  Oncotarget       Date:  2016-12-06

4.  Leptin rs2167270 G > A (G19A) polymorphism may decrease the risk of cancer: A case-control study and meta-analysis involving 19 989 subjects.

Authors:  Jing Yang; Zhihui Zhong; Weifeng Tang; Jianping Chen
Journal:  J Cell Biochem       Date:  2019-01-29       Impact factor: 4.429

5.  The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis.

Authors:  Lilong Zhang; Qihang Yuan; Man Li; Dongqi Chai; Wenhong Deng; Weixing Wang
Journal:  BMC Cancer       Date:  2020-11-30       Impact factor: 4.430

6.  The Prognosis of Leptin rs2167270 G > A (G19A) Polymorphism in the Risk of Cancer: A Meta-Analysis.

Authors:  Aiqiao Zhang; Shangren Wang; Fujun Zhang; Wei Li; Qian Li; Xiaoqiang Liu
Journal:  Front Oncol       Date:  2021-11-18       Impact factor: 6.244

7.  Investigation of LEP and LEPR polymorphisms with the risk of hepatocellular carcinoma: a case-control study in Eastern Chinese Han population.

Authors:  Sheng Zhang; Jiakai Jiang; Zhan Chen; Yafeng Wang; Weifeng Tang; Chao Liu; Longgen Liu; Yu Chen
Journal:  Onco Targets Ther       Date:  2018-04-11       Impact factor: 4.147

8.  Leptin gene variants and colorectal cancer risk: Sex-specific associations.

Authors:  Kelsey A Chun; Jonathan M Kocarnik; Sheetal S Hardikar; Jamaica R Robinson; Sonja I Berndt; Andrew T Chan; Jane C Figueiredo; Noralane M Lindor; Mingyang Song; Robert E Schoen; Richard B Hayes; John D Potter; Rami Nassir; Stéphane Bézieau; Loic Le Marchand; Martha L Slattery; Emily White; Ulrike Peters; Polly A Newcomb
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.